A new preventive vaccine trial, Intercept‑Lynch, will begin this summer to assess an mRNA‑based shot (mRNA‑4194) designed to stop pre‑cancerous cells in people with Lynch syndrome. the collaboration between the University of Oxford,Moderna and Cancer Research UK hopes to curb bowel, ovarian and other cancers that afflict roughly 10,000 diagnosed carriers in England.

Intercept‑Lynch trial to launch summer 2024

The first phase of Intercept‑Lynch will enroll participants this summer, focusing on safety, dosage and immune‑response profiling , according to the trial announcement. researchers will monitor how the vaccine trains T‑cells to recognise abnormal proteins that appear in early lesions of Lynch‑related tumours.

mRNA‑4194 targets shared Lynch‑syndrome antigens

Professor David Church, lead investigator at Oxford,explained that the vaccine’s antigens are common across the spectrum of cancers linked to mismatch‑repair gene mutations. By presenting these shared markers,mRNA‑4194 aims to give broad protection against bowel, ovarian, stomach and several other tumour types.

Oxford‑Moderna partnership backd by Cancer Research UK

The trial is a joint effort between the University of Oxford and Moderna, with funding and scientific support from Cancer Research UK. David Berman, Moderna’s chief development officer, said the partnership leverages COVID‑19 mRNA expertise to intervene early in the patient journey, maximising the immune system’s impact.

Unclear timeline for regulatory approval after Phase 2

While Phase 1 will determine safety, the path to a licensed preventive vaccine remains uncertain; regulators have not yet outlined criteria for a cancer‑prevention indication. Moreover, a multi‑centre Phase 2 is slated for 2027, leaving a gap of several years before any potential public rollout.

Who remains unaware of their Lynch‑syndrome status?

Only about 5 % of the estimated 175,000 English carriers know they have the condition, highlighting a gap in genetic testing and counselling that could limit trial recruitment, as the source notes.